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insufficient with monotherapy. We evaluated the cost and resource utilisation, in 
the UK health care system, of three treatment scenarios: tamsulosin (0.4mg) mon-
otherapy; tolterodine (modified release, 4mg) + tamsulosin given concomitantly; 
and fixed-dose combination (FDC) of solifenacin 6mg + oral controlled absorption 
system [OCAS™] formulation of tamsulosin (TOCAS, 0.4mg). Methods: A Markov 
model, with a monthly cycle length and 1-year time horizon, compared the cost of 
treating 1,000 men with LUTS/BPH who have moderate-to-severe storage symp-
toms and voiding symptoms. All patients were initially treated with tamsulosin 
monotherapy. Patients with inadequately controlled symptoms at week 12, based 
on Total Urgency and Frequency Score (TUFS, the daily sum of all recorded Patient 
Perception of Intensity of Urgency Scale [PPIUS] scores from micturition diaries), 
were considered for FDC solifenacin 6mg + TOCAS or tolterodine + tamsulosin. 
Patients adequately controlled at week 12 continued tamsulosin monotherapy. 
Thereafter, patients could discontinue therapy each month based on reported 
medication persistence data. Patients who discontinued treatment were eligible 
for surgery or other medical management. Results: Compared with tamsulosin 
monotherapy, total costs per patient, over a 1-year time horizon, were reduced by 
£133.75 for tolterodine + tamsulosin and reduced by £154.85 for FDC solifenacin 
6mg + TOCAS. ConClusions: Our findings suggest FDC solifenacin 6mg + TOCAS 
reduces annual health care costs compared with tamsulosin monotherapy and 
tolterodine + tamsulosin in patients with inadequately controlled storage symp-
toms. Lower total cost for FDC solifenacin 6mg + TOCAS and tolterodine + tamsu-
losin versus tamsulosin monotherapy was largely driven by improved symptom 
control. The relatively lower total cost for FDC solifenacin 6mg + TOCAS versus 
tolterodine + tamsulosin (£21 per patient/year) was principally due to improved 
persistence with FDC solifenacin 6mg + TOCAS.
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objeCtives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
insufficient with monotherapy. We evaluated the cost-effectiveness of fixed-dose 
combination (FDC) solifenacin 6mg + oral controlled absorption system (OCAS™) 
formulation of tamsulosin (TOCAS, 0.4mg) versus tolterodine (modified release, 
4mg) + tamsulosin (0.4mg) given concomitantly, from the perspective of the UK 
NHS. Methods: A Markov model, with a time horizon of 1 year, was developed for 
men with LUTS/BPH who have moderate-to-severe storage symptoms (≥ 8 micturi-
tions/day and ≥ 2 urgency episodes/day [Patient Perception of Intensity of Urgency 
Scale, PPIUS, grade 3 or 4]) and voiding symptoms treated with FDC solifenacin 
6mg + TOCAS or tolterodine + tamsulosin. Treatment success was defined using 
the Total Urgency and Frequency Score (TUFS, the daily sum of all recorded PPIUS 
scores from micturition diaries). The phase 3 NEPTUNE study was used to estimate 
transition probabilities and utilities were derived from analysis of EQ-5D data. Other 
model input parameters included discontinuation rates, derived from a large UK 
database study (THIN). Univariate and probabilistic sensitivity analyses were per-
formed. Results: FDC solifenacin 6mg + TOCAS was associated with lower total 
annual costs (£520 vs £583) and increased quality adjusted life years (QALYs, 0.840 
vs. 0.838), and was therefore dominant compared with tolterodine + tamsulosin. 
Time horizon, discontinuation/withdrawal rates, drug cost and utility values were 
the main drivers of cost-effectiveness. The probability that FDC solifenacin 6mg + 
TOCAS is cost-effective was 100% versus tolterodine + tamsulosin, at a willingness 
to pay threshold of £20,000/QALY gained. ConClusions: FDC solifenacin 6mg + 
TOCAS is dominant compared with tolterodine + tamsulosin for the treatment of 
men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding 
symptoms. To our knowledge, this is the first cost-effectiveness analysis of a FDC 
in this patient population.
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objeCtives: The most recent literature has shown extensively that a low protein 
diet in patients with Chronic Kidney Disease (CKD), delays the natural progres-
sion of the end stage renal disease (ESRD) and the necessary treatment of chronic 
dialysis. The aim of this study is to estimate the cost-effectiveness of a low protein 
diet compared with no dietary treatment in patients with CKD stage 4 and 5 after 
2, 3, 5 and 10 years. Methods: It was developed a Markov model to estimate 
costs and QALYs associated with low protein diet versus no treatment for patients 
with CKD stage 4-5. The transition probability was estimated on data from seven 
studies which determined the efficacy of low protein diets in delaying the need 
to start maintenance dialysis. Utilities and cost were estimated from literature 
review and projected for the lifespan considered in the model. The annual cost 
of dialysis per patient was approximately € 34,072. The costs of a low-protein diet 
was € 1,440 per patient per year in the Lazio Region (conservative assumptions). 
Probabilistic and Deterministic sensitivity analysis were performed. Results: The 
model estimate that low-protein diet should be more effective. Dietary treatment 
improve 0.09 QALYs after two years, 0.16 after three years, 0.36 after five years and 
up to 0.93 incremental QALYs after the first 10 years. After two years the model 
estimate incremental cost in favour of dietary treatment of € 1,325, € 3,023, € 6,906 
and € 13,829 for 2, 3, 5 and 10 years of follow-up respectively. ConClusions: The 
results of these simulations indicate that the treatment of CKD patients with a 
objeCtives: To analyze the cost of hemodialysis (HD) and peritoneal dialysis (PD) 
in different regions of Russia. Methods: Open source information search. Direct 
cost analysis. Results: During the information search current tariffs have been 
found for 25 regions for HD and for 11 regions for PD. Tariff per one HD procedure 
has ranged from $ 96 for the republic Chuvashia to $ 319 for the the Khanty-Mansi 
Autonomous Area, i.e. annual cost of the HD per patient amounted to $ 14976 
and $ 49764, respectively. The cost of a single procedure HD in Moscow was $ 162, 
which corresponds to an annual expenditure of approximately $ 25272 per patient. 
 The average cost of the procedure HD in the Russia amounted to about $ 150 
and the annual cost of HD for one patient - $ 23400. The cost of one exchange 
PD ranged from $ 15 in the Nizhny Novgorod region to $ 84 in the Khanty-Mansi 
Autonomous Area. Thus, the annual costs on the PD upon 4 exchanges per day for 
per patient in these regions were $ 21900 and $ 122640, respectively. The cost of 
one PD exchange in Moscow was $ 26, which corresponds to an annual expendi-
ture of approximately $ 37960 per patient. The average cost of one exchange PD 
in Russia amounted to $ 22, and the average annual cost per patient - $ 32120 
(accepted exchange rate was 1 $ = 33,35 RUB). ConClusions: Thus, during the 
cost analysis it has been revealed that the cost of dialysis among the subjects of 
Russia differs in more than 3 times, despite the fact that the same set of medical 
services is provided in each region.
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objeCtives: To understand the trends in rate and cost of hospitalizations due 
to Chronic Kidney Disease (CKD) in the U.S. Methods: We analyzed the last five 
years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal 
Disease (ESRD). The annual number of hospitalizations for specific diagnosis was 
obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. 
Data was also analyzed for length of stay (LOS), charges and cost of hospitaliza-
tion. Results: During the last five years the number of hospitalizations with 
diagnosis of CKD and ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, 
an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of CKD 
and ESRD respectively. The mean LOS for patients with CKD increased from 4.9 to 
5.5 days between2005-2009. The mean LOS for patients with ESRD has remained 
steady at ~6 days between 2005-2009. The cost of hospitalization with diagnosis 
of CKD has increased 31% between 2005-2009. The cost of hospitalization with 
diagnosis of ESRD has increased 21% between 2005-2009. In 2009, the mean cost of 
hospitalization for patients with CKD and ESRD was $11,209 and $21,358, respec-
tively. ConClusions: Hospitalizations due to CKD and ESRD have significantly 
increased during the last five years. There is a need for prevention, treatment, and 
disease management programs to lower the medical and socioeconomic burden 
of this disease.
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objeCtives: Although delayed graft function (DGF) on kidney transplantation 
outcomes have been associated with worse allograft and patient survival, the cost 
impact has not been recently explored using a large retrospective database and 
assessed after transplantation hospitalization. Our objective was to determine the 
financial impact of delayed graft function (DGF) in primary kidney transplant recipi-
ents of deceased (DD) and living donor (LD) recipients in the early post-operative 
and long-term follow-up periods. Methods: A retrospective analysis of USRDS 
and Medicare claims from 2004-2009. Subjects excluded were multiple transplants, 
donor < 5 yo, and transplantation payments < $15,000. DGF was defined at requiring 
dialysis within the first week post-transplantation. Total direct medical costs were 
assessed for 1, 3, 6, 12, 24, and 36-month time intervals post-transplant. Uni-variate 
analyses of covariates were assessed for association with log-transformed charges. 
Significant variables (p< 0.05) were included in multivariate regression. Base charge 
was calculated using an mean of standard demographic and outcome characteris-
tics. Results: After application of exclusion criteria and data validation, 22,616 DD 
and 7,373 LD recipients were evaluated. In multivariate analysis, DGF was an inde-
pendent predictor of charges at 1, 3, 6, and 12 months of $3,920 (p< 0.0001), $1,962 
(p< 0.0001), $839 (p= 0.006) and $1,026 (p= 0.019), respectively in DD. In LD, DGF was 
an independent predictor of charges at 1, 3, and 6 months of $145 (p= 0.012), $4,558 
(p< 0.0001), and $3,629 (p= 0.001), respectively. ConClusions: DGF is a significant 
independent predictor of greater health resource utilization in renal transplanta-
tion that impacts costs beyond the transplant hospitalization. This impact extends 
longer in DD compared to LD. This information should be considered in addition to 
clinical outcomes expected based on the individual transplant candidate to deter-
mine likelihood of successful patient and allograft outcomes.
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objeCtives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
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UrinAry/KidnEy disordErs – Patient-reported outcomes & Patient Preference 
studies
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objeCtives: Adherence to immunosuppressive therapy after kidney transplanta-
tion is crucial to avoid graft rejection and optimise long term patient and graft 
survival. However, patient’s adherence is not always optimal. Our aim was to identify 
reasons for non-adherence and health-related quality of life (HRQoL) dimensions 
affected by immunosuppressant therapy (IT) after kidney transplantation (KT) 
including patient preference of once daily over twice daily immunosuppressive 
regimen. Methods: A literature review on adherence to immunosuppressant ther-
apy (IT) and impact of IT on HRQoL through the EMBASE database was performed. 
Interviews were conducted with 2 clinical experts to determine key concepts related 
to KT and immunosuppressants. Thirty-six patients in four focus groups were asked 
to cite important concepts related to adherence and impact of IT on HRQoL and rate 
them. Qualitative analysis was conducted to code patient’s responses. Results: 
The results showed that non-adherence was mostly unintentional among the par-
ticipants. The reason for non-adherence included forgetfulness, interference with 
lifestyle, being asleep at the time the medication should be taken, change in routine 
and impact of side effects. The twice daily regimen was more problematic in relation 
to adherence. Overall, participants were of the opinion that a once daily IT regimen 
would help them be more adherent. Also, IT impacts on the HRQoL of the patient 
in a number of ways including: restricting the patients’ lifestyle, causing anxiety or 
impairing the patient’s ability to work. Although the patients happily oblige to the 
necessity of taking IT medication, patients preferred to reduce the burden associ-
ated with medication. ConClusions: This study suggested that patients strongly 
valued adherence to IT medication and saw a change in the regimen from twice 
daily to once daily as one way to improve their adherence to IT. Results also sug-
gested that a once daily regimen could improve patient’s HRQoL.
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objeCtives: Although pivotal studies of overactive bladder (OAB) medications 
routinely use micturition frequency (MF) when defining the primary or coprimary 
endpoint, few studies have examined minimal important difference (MID) values 
for this parameter. This study explored MID values for MF using data from a Phase 
IIb study in OAB patients with urge predominant incontinence along with esti-
mates for OAB symptoms of urinary urgency (UU), urgency incontinence (UUI), 
and total incontinence (TI). Methods: The endpoint was defined as the change 
from baseline to 8 weeks in the number of daily episodes averaged over a diary 
week for each parameter. Anchor- and distribution-based methods using statisti-
cal criteria (e.g. half standard deviation) were used to estimate MID ranges for all 
diary parameters. Anchors were selected as a +1 change score representing slight 
improvement for global assessment questions assessing frequency and control 
over OAB symptoms. Results: The sample included 769 OAB patients with (80.4%) 
and without (19.6%) incontinence. The baseline mean number of micturitions was 
11 and the mean (%) change from baseline representing the MID for MF ranged 
from 1.6-1.8 (14.3-16.4%). For urgency, the baseline and mean (%) change was 7 and 
2.4-2.5 (42.7-47.2%), respectively. For total incontinence, the baseline and mean (%) 
change was 3 and 1.5-1.7 (64.3-76.2%), respectively, with similar values for UUI. 
Distribution-based values were much smaller than those derived using anchor-
based methods. ConClusions: The mean changes representing MID estimates 
for micturition frequency were comparable to those observed for incontinence but 
constituted smaller percent changes given the larger number of baseline micturi-
tions. The MID estimates for MF were smaller than the MID estimates for urgency. As 
MID estimates derived for OAB patients have focused mainly on incontinence, these 
results present useful information for designing studies which routinely include 
change in micturition frequency as the primary endpoint of interest.
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objeCtives: To evaluate health-related quality of life (HRQoL) assessment in chil-
dren and adolescents with chronic kidney disease (CKD). Methods: A systematic 
literature search was conducted using PubMed, MEDLINE, PsycINFO, and CINAHL 
from the inception of each database until October 2013. Search terms included 
kidney disease, children (or adolescents), health-related quality of life, and instru-
ment. The following inclusion criteria were applied to the studies: (1) published in 
English, (2) in a peer reviewed journal, (3) about children or adolescents with CKD 
or end-stage renal disease (ESRD), and (4) had one of the following outcomes—
development/validation of a disease-specific HRQoL instrument OR use of HRQoL 
as a primary outcome. A modified minimum data checklist developed by Efficace 
and colleagues was used to evaluate the quality of studies that report HRQoL out-
comes. The consensus-based standards for the selection of health measurement 
instruments (COSMIN) was used to evaluate the methodological quality of studies 
that report on the development or validation of HRQoL instruments. Results: A 
low protein diet is cost effective relative to no-treatment in an Italian setting. 
Further studies should test this model in other countries with different dialysis 
costs and dietary support.
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objeCtives: Induction therapy is administered at the time of kidney transplan-
tation to prevent acute rejections. The agent of choice depends on the degree of 
patient risk for acute rejection. In the US, rabbit anti-thymocyte globulin (rATG) 
is the standard agent administered to high-risk patients. A monoclonal antibody 
approved for use in chronic lymphocytic leukemia—alemtuzumab—has been 
shown in off-label use to be equally safe and efficacious as rATG in these patients. 
Furthermore, alemtuzumab costs less, making it a potentially cost-effective alter-
native. Nevertheless, practitioners have been slow to adopt alemtuzumab as an 
induction agent of choice due to concerns that it may be less effective than rATG 
in improving patient survival in the long-term. The objective of this study is to 
the project the incremental cost-effectiveness ratio (ICER) of alemtuzumab versus 
rATG in high-risk patients. Methods: A decision-analytic model was constructed 
to model costs and outcomes specific to the first 12 months post-transplantation, 
such as for delayed graft function and acute rejection; long-term (30-year) out-
comes were estimated with a Markov model with outcomes measured in life 
years (LYs) and quality-adjusted life years (QALYs). Clinical probabilities were 
obtained from randomized controlled trials; preference weights from direct patient 
measures in previously published literature; and costs from previously published 
cost-effectiveness studies on kidney transplantation. Results: In the base case, 
alemtuzumab was projected to yield 1.18 LYs and 1.09 QALYs gained when com-
pared with rATG. The estimated ICER of alemtuzumab compared to rATG was 
$5,368 per QALY. Sensitivity analysis revealed that the ICER was most sensitive 
to the transition probabilities to graft loss and death. Despite these variations, 
alemtuzumab was cost-effective across all parameter ranges, with the greatest 
ICER being $21,133. ConClusions: In kidney transplant patients at high risk of 
acute rejection, our model suggests that alemtuzumab is likely to be cost-effective, 
yielding an ICER below often-cited thresholds.
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Cost Utility AnAlysis of sACrAl nEUromodUlAtion vErsUs botox A in 
thE trEAtmEnt of ovErACtivE blAddEr in ColombiA
Castaño JC1, Lopera A.1, Orozco J.J.2, Valencia J.E.2
1Hospital Pablo Tobon Uribe, Medellin, Colombia, 2Medtronic Latinamerica Inc., Bogota, Colombia
objeCtives: Cost Utility Analysis of Sacral Neuromodulation (SNM) vs. 
botulin toxin type A (BoNTA) in Overactive Bladder (OAB) treatment in 
Colombia. Methods: Through the adaptation of an HTA Consulting economic 
model and after data transferability analysis, a cost-utility analysis of SNM vs. 
BoNTA 100UI in the treatment of OAB in Colombia was done. The model was 
constructed as a Discrete Event Simulation. The effectiveness data of SNM and 
BoNTA, defined as more than 50% improvement in urinary parameters, was based 
on studies identified in systematic review Jaros 2013 conducted in Polish settings. 
Based in systematic search for health-related quality of life data, one health state 
for treatment success and one for treatment failure were defined, as well as disu-
tility related to treatment. The costs data was obtain from the Colombian Public 
Reimbursement Tariff Manual and from urologist medical group specialized in 
OAB treatment, which also reviewed and adjusted the frequency of resources use. 
A 10 years horizon and a 3% discount rate were used. Deterministic and probabil-
istic sensitive analyses were done. Results: The treatment with SNM obtained 
5.67 QALYs vs. 5.38 QALYs obtained with BoNTA with 0.28 incremental QALYs. 
The total costs were US$27,828 vs. US$28,906, with minus US$1,077 incremental 
Dollars. Because SNM was more effective and less costly, dominates to BoNTA, 
meaning that is cost-saving respect to this. 49.1% of the simulations in the 
Probabilistic Sensitivity analysis were in the NE quadrant, more effective and more 
costly, and 50.9% in the SE quadrant, more effective and less costly than BoNTA, 
and 100% under the threshold of 3 Colombian GDP Per Capita. ConClusions: 
SNM has a higher effectiveness than BoNTA in terms of Quality of Life at a lower 
cost and compared to BoNTA is a cost-saving therapy for the treatment of OAB 
in Colombia.
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objeCtives: The aim of this study was to conduct an economic evaluation to 
compare utility and costs of very low-protein diet, low-protein diet and full-
protein diet in CKD patients in China. Methods: A cost-utility analysis was 
conducted in a hypothetical population with GFR≤ 25ml/min/1.73m42 in 5 years. 
Based on the literature data, patients’ disease progressions with different diets 
are generated in 5 years. Cost data was collected by medical insurance data-
base and out-patient survey. EQ-5D was used to collect patients’ quality of life 
score. Results: In 5 years, patients with full-protein diet had the highest cost 
of CNY520786.8, followed by patients with low-protein diet (CNY503440.3), and 
patients with very-low-protein diet (CNY475066.7). Patients with very-low-protein 
diet had the highest quality-adjusted life-years(4.329),followed by patients with 
low-protein diet (4.036), and patients with full-protein diet(3.980). ConClusions: 
The protein-restricted diet can delay the time of dialysis and then reduce 
patients’ burden and improve patients’ quality of life. In this way, the very-low-
protein diet is the optimal way.
